GSK Leverages Higher Return On OTC R&D Investment To Drive Growth – Witty

GlaxoSmithKline will be investing more R&D dollars in its consumer health care business, where spending on innovation pays off more quickly and more consistently than in the prescription sector, CEO Andrew Witty says